BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1037 related articles for article (PubMed ID: 12360430)

  • 1. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
    Prieto M; Gómez MD; Berenguer M; Córdoba J; Rayón JM; Pastor M; García-Herola A; Nicolás D; Carrasco D; Orbis JF; Mir J; Berenguer J
    Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
    Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
    Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Settmacher U; Neuhaus R; Radke C; Berg T; Hopf U; Neuhaus P
    Liver Transpl; 2001 Nov; 7(11):976-82. PubMed ID: 11699034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation.
    Shitrit AB; Kramer MR; Bakal I; Morali G; Ben Ari Z; Shitrit D
    Ann Thorac Surg; 2006 May; 81(5):1851-2. PubMed ID: 16631684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation.
    Segovia R; Sánchez-Fueyo A; Rimola A; Grande L; Bruguera M; Costa J; Soguero C; Uriz J
    Liver Transpl; 2001 Feb; 7(2):106-12. PubMed ID: 11172393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure.
    Abdelmalek MF; Pasha TM; Zein NN; Persing DH; Wiesner RH; Douglas DD
    Liver Transpl; 2003 Dec; 9(12):1253-7. PubMed ID: 14625824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
    Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
    Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical course of de novo hepatitis B infection after pediatric liver transplantation.
    Su WJ; Ho MC; Ni YH; Wu JF; Jeng YM; Chen HL; Wu YM; Hu RH; Chang MH; Lee PH
    Liver Transpl; 2010 Feb; 16(2):215-21. PubMed ID: 20104496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool.
    Donataccio D; Roggen F; De Reyck C; Verbaandert C; Bodeus M; Lerut J
    Transpl Int; 2006 Jan; 19(1):38-43. PubMed ID: 16359375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome.
    Rokuhara A; Tanaka E; Yagi S; Mizokami M; Hashikura Y; Kawasaki S; Kiyosawa K
    J Med Virol; 2000 Dec; 62(4):471-8. PubMed ID: 11074476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic alteration of HBV markers on active HBV replicative recipients after liver transplantation: a preliminary report.
    Lu SC; Yan LN; Li B; Ma YK; Liu C; Wen TF; Lin QY; Zhao JC; Wang XB; Li XD; Qing S; Zhao LS; Liu C; Liu J; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):196-201. PubMed ID: 14599968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance.
    Ghisetti V; Marzano A; Zamboni F; Barbui A; Franchello A; Gaia S; Marchiaro G; Salizzoni M; Rizzetto M
    Liver Transpl; 2004 Mar; 10(3):356-62. PubMed ID: 15004761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.